A detailed history of Hantz Financial Services, Inc. transactions in Northwest Biotherapeutics Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 250 shares of NWBO stock, worth $70. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 250 -0.0%
Holding current value
$70
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$0.42 - $0.55 $105 - $137
250 New
250 $0

Others Institutions Holding NWBO

About NORTHWEST BIOTHERAPEUTICS INC


  • Ticker NWBO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,037,230,016
  • Market Cap $290M
  • Description
  • Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, wh...
More about NWBO
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.